+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 16Years +
All Genders
ID04566380

Multicenter Open-Label Study Evaluating Long-Term Safety of ONO-4538 Alone or With Other Therapies in Patients With Various Tumors

Led by Ono Pharmaceutical Co., Ltd. · Updated on 2026-10-14

70

Participants Needed

44

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the long-term safety of the drug ONO-4538 in participants with various types of tumors. This phase II study includes individuals who have previously been treated with ONO-4538 either alone or combined with other therapies in clinical trials. The goal is to monitor safety over an extended period to better understand the effects of continuing ONO-4538 treatment. Participants receive ONO-4538 either as monotherapy or in combination with other treatments such as S-1 plus oxaliplatin, capecitabine plus oxaliplatin, bevacizumab, temozolomide, ipilimumab plus combination therapies, or ONO-7703. ONO-4538 is given by intravenous infusion every 2 to 4 weeks depending on the investigators choice, while combination therapies include various oral and intravenous drugs administered according to specific schedules. The study continues the treatment regimens from prior clinical trials. During the study, participants are monitored for adverse events from the start of treatment until 28 days after the treatment phase ends. Researchers assess safety through regular evaluations and record any side effects experienced. Participation continues as long as treatment is ongoing, helping to provide detailed long-term safety data for ONO-4538 in this patient population.

CONDITIONS

Brief Title

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Research Team

N

North America Clinical Trial Support Desk

I

International Clinical Trial Support Desk

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here